Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Targeted Oncology

Volumn 6, Issue 1, 2011, Pages 5-16

  Pal, Sumanta Kumar ^a   Figlin, Robert A ^b,c,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Academic Program Development   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BeST; Biomarkers; Clinical trials; Deferolimus; Everolimus; INTORACT; mTOR; Temsirolimus; TORAVA

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BNC 105P; BRYOSTATIN 1; ERLOTINIB; EVEROLIMUS; IMATINIB; LENALIDOMIDE; LENVATINIB; LY 2584702; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MK 2206; NAVELBINE; NELFINAVIR; PANOBINOSTAT; PAZOPANIB; PLACEBO; RO 4929097; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; VATALANIB; VINORELBINE DITARTRATE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; COLON FISTULA; COLON HEMORRHAGE; DRUG COMPETITION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHRECTOMY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79957444423     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0172-y     Document Type: Review

References (113)

1. The Pharma Letter (1992, May) Available at: http://www.thepharmaletter. com/file/45036/chirons-il-2-approved-in-usa.html ; last accessed December 2, 2010
2. G Fyfe RI Fisher SA Rosenberg M Sznol DR Parkinson AC Louie 1995 Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 3 688 696 7884429 1:STN:280:DyaK2M7ptVGiuw%3D%3D
3. RJ Motzer J Bacik BA Murphy P Russo M Mazumdar 2002 Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 1 289 296 10.1200/jco.20.1.289 11773181 10.1200/JCO.20.1.289 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D (Pubitemid 34032623)
4. FDA Approval Letter for Sorafenib. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/appletter/2005/021923ltr.pdf ; last accessed March 24, 2010
5. FDA Approval Letter for Sunitinib. Available at http://www.accessdata. fda.gov/drugsatfda-docs/appletter/2006/021968s000ltr.pdf ; last accessed March 24, 2010
6. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski the TARGET Study Group 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 125 134 10.1056/NEJMoa060655 17215530 10.1056/NEJMoa060655 1:CAS:528: DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
7. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 115 124 10.1056/NEJMoa065044 17215529 10.1056/NEJMoa065044 1:CAS:528: DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
8. B Escudier J Bellmunt S Negrier E Bajetta B Melichar S Bracarda A Ravaud S Golding S Jethwa V Sneller 2010 Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 13 2144 2150 10.1200/jco.2009.26. 7849 20368553 10.1200/JCO.2009.26.7849 1:CAS:528:DC%2BC3cXpsFSgsbo%3D
9. BI Rini S Halabi JE Rosenberg WM Stadler DA Vaena L Archer JN Atkins J Picus P Czaykowski J Dutcher EJ Small 2010 Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 13 2137 2143 10.1200/jco.2009.26.5561 20368558 10.1200/JCO.2009.26.5561 1:CAS:528: DC%2BC3cXpsFSgsbw%3D
10. CN Sternberg ID Davis J Mardiak C Szczylik E Lee J Wagstaff CH Barrios P Salman OA Gladkov A Kavina JJ Zarba M Chen L McCann L Pandite DF Roychowdhury RE Hawkins 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 1061 1068 10.1200/jco.2009.23.9764 20100962 10.1200/JCO.2009.23.9764 1:CAS:528: DC%2BC3cXktF2lt78%3D
11. RJ Motzer B Escudier S Oudard TE Hutson C Porta S Bracarda V Grunwald JA Thompson RA Figlin N Hollaender G Urbanowitz WJ Berg A Kay D Lebwohl A Ravaud 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 449 456 10.1016/S0140-6736(08)61039-9 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
12. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IGH Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer the Global ARCC Trial 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2271 2281 10.1056/NEJMoa066838 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
13. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 28(15s):abstr 3005
14. SK Pal RA Figlin KL Reckamp 2008 The role of targeting mammalian target of rapamycin in lung cancer Clin Lung Cancer 9 6 340 345 10.3816/CLC.2008.n.049 19073516 10.3816/CLC.2008.n.049 1:CAS:528:DC%2BD1MXlvF2mtQ%3D%3D
15. C Eimer H Gerullis C Heuck T Otto 2011 mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome? Anticancer Drugs 22 1 18 23 10.1097/CAD.0b013e3283407dde 21037468 10.1097/CAD.0b013e3283407dde 1:CAS:528:DC%2BC3cXhsVOktbrN
16. H Gerullis TH Ecke C Eimer CJ Heuck T Otto 2010 mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review Minerva Urol Nefrol 62 4 411 423 R19101845 20944541 1:STN:280:DC%2BC3cfptlajtg%3D%3D
17. SK Pal RA Figlin 2010 Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors Clin Med Insights Oncol 4 43 53 20711245 1:CAS:528:DC%2BC3cXnslWhuro%3D
18. A Pinto Marin A Redondo Sanchez E Espinosa Arranz P Zamora Aunon B Castelo Fernandez M Gonzalez Baron 2010 mTOR pathway inhibition in renal cell carcinoma Urol Oncol S1078-1439(09)00361-5 20207176
19. GR Hudes 2009 Targeting mTOR in renal cell carcinoma Cancer 115 10 Suppl 2313 2320 10.1002/cncr.24239 19402072 10.1002/cncr.24239 1:CAS:528: DC%2BD1MXmtVOktr4%3D
20. BI Rini 2008 Update on the use of mTOR inhibitors in renal cell carcinoma Clin Adv Hematol Oncol 6 10 722 724 18997660
21. Fischer P, Patel P, Carducci MA, McDermott DF, Hudes GR, Lubiniecki GM, Gelder MS, Senico P, Curiel RE, Motzer RJ (2008) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol 26(May 20 suppl):abstr 16020
22. RK Kelley HS Nimeiri MT Vergo EK Bergsland AH Ko PN Munster A Reinert MF Mulcahy AB Benson AP Venook 2010 A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) ASCO Meet Abstr 28 15
23. KB Kim MA Davies NE Papadopoulos AY Bedikian W Hwu K Woodard EW Washington JE Dancey J Wright P Hwu 2009 Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma ASCO Meet Abstr 27 15S 9026
24. PY Wen T Cloughesy J Kuhn K Lamborn LE Abrey F Lieberman HI Robins J Wright MD Prados M Gilbert 2009 Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02) ASCO Meet Abstr 27 15S 2006
25. A Patnaik A Ricart J Cooper K Papadopoulos M Beeram C Mita MM Mita D Hufnagel E Izbicka AW Tolcher I National Cancer 2007 A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies ASCO Meet Abstr 25 18-suppl 3512
26. RJ Motzer BI Rini RM Bukowski BD Curti DJ George GR Hudes BG Redman KA Margolin JR Merchan G Wilding MS Ginsberg J Bacik ST Kim CM Baum MD Michaelson 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 21 2516 2524 10.1001/jama.295.21.2516 16757724 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D (Pubitemid 43854967)
27. Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC, Maples W, Erlichman C (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 27(15s):abstr 5039
28. JR Merchan HC Pitot R Qin G Liu TR Fitch J Picus WJ Maples C Erlichman 2009 Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients J Clin Oncol (Meet Abstr) 27 15S 5039
29. NCT00631371: study comparing bevacizumab + temsirolimus vs. bevacizumab + interferon-alfa in advanced renal cell carcinoma subjects (INTORACT). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
30. NCT00378703: the BeST trial: a randomized phase II study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST]. Available at: http://www.clinicaltrials.gov. Accessed December 22, 2009
31. Bhargava P, Esteves B, Al-Adhami M, Nosov D, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval D, Slichenmyer WJ (2010) Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 28(15s):abstr 4599
32. Kabbinavar FF, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Dhillon R, Cotreau MM, Al-Adhami M, Bhargava P, Fishman MN (2010) Combination of tivozanib (AV-951) and temsirolimus in patients with renal cell carcinoma: preliminary results from a phase 1 trial. Presented at the 2010 Kidney Cancer Symposium on October 2, 2010 in Chicago, IL [Abstr 49]
33. Cen P, Daleiden A, Doshi G, Amato R (2009) A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:abstr e1605
34. Kroog GS, Feldman DR, Kondagunta GV, Ginsberg MS, Fischer PM, Trinos MJ, Patil S, Ishill NM, Motzer RJ (2009) Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s):abstr 5037
35. Zafar Y, Bendell J, Lager J, Yu D, George D, Nixon A, Petros W, Beci R, Arrowood C, Hurwitz H (2006) Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. J Clin Oncol 24(18s):abstr 3097
36. JD Hainsworth DR Spigel HA Burris D Waterhouse BL Clark R Whorf 2010 Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 13 2131 2136 20368560 10.1200/JCO.2009.26.3152 1:CAS:528:DC%2BC3cXpsFSgsb4%3D
37. NCT00719264: a randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney. Available at: http://www.clinicaltrials.gov. Accessed December 22, 2009
38. NCT01217931: sequential two-agent assessment in renal cell carcinoma therapy. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
39. NCT00474786: temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
40. NCT00326898: sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. Available at: http://www.clinicaltrials.gov ; last accessed December 10, 2010
41. NCT00375674: a clinical trial comparing efficacy and safety of sunitinib versus placebo for thetreatment of patients at high risk of recurrent renal cell cancer (S-TRAC). Available at: http://www.clinicaltrials.gov ; last accessed December 10, 2010
42. NCT00492258: sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. Available at: http://www. clinicaltrials.gov ; last accessed December 10, 2010
43. NCT01120249: everolimus in treating patients with kidney cancer who have undergone surgery. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
44. CL Cowey C Amin RS Pruthi EM Wallen ME Nielsen G Grigson C Watkins KV Nance J Crane M Jalkut DT Moore WY Kim PA Godley YE Whang JR Fielding WK Rathmell 2010 Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 9 1502 1507 10.1200/JCO.2009.24.7759 20159822 10.1200/JCO.2009.24.7759 1:CAS:528: DC%2BC3cXltFGhsbo%3D
45. AA Thomas BI Rini BR Lane J Garcia R Dreicer EA Klein AC Novick SC Campbell 2009 Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2 518 523 10.1016/j.juro.2008.10. 001 19100579 10.1016/j.juro.2008.10.001 1:CAS:528:DC%2BD1MXitVWiu7g%3D discussion 523
46. NJ Hellenthal W Underwood R Penetrante A Litwin S Zhang GE Wilding BT Teh HL Kim 2010 Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma J Urol 184 3 859 864 10.1016/j.juro.2010.05.041 20643461 10.1016/j.juro.2010.05.041 1:CAS:528:DC%2BC3cXpvVejtLY%3D
47. NCT01107509: pilot study of neo-adjuvant everolimus to treat advanced renal cell carcinoma-analysis of biomarkers. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
48. TK Choueiri A Plantade P Elson S Negrier A Ravaud S Oudard M Zhou BI Rini RM Bukowski B Escudier 2008 Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 1 127 131 18165647 10.1200/JCO.2007.13.3223 1:CAS:528:DC%2BD1cXhsVCrtr4%3D
49. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM (2010) Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study. J Clin Oncol 28(15s):abstr 4604
50. NCT00979966: study in Non-clear cell Renal Carcinoma (Ncc-RCC) temsirolimus versus sunitinib. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
51. NCT01108445: phase II study of afinitor vs. sutent in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
52. NCT00830895: RAD001 for non-clear cell Renal Cell Carcinoma (RCC). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
53. NCT00688753: RAPTOR: RAD001 as monotherapy in the treatment of advanced papillary renal cell tumors program in Europe (RAPTOR/LFR08). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
54. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 123 132 10.1056/NEJMoa050753 16014882 10.1056/NEJMoa050753 1:CAS:528: DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
55. CH Chung B Mirakhur E Chan QT Le J Berlin M Morse BA Murphy SM Satinover J Hosen D Mauro RJ Slebos Q Zhou D Gold T Hatley DJ Hicklin TA Platts-Mills 2008 Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose N Engl J Med 358 11 1109 1117 10.1056/NEJMoa074943 18337601 10.1056/NEJMoa074943 1:CAS:528:DC%2BD1cXjt1aitLk%3D (Pubitemid 351398485)
56. NCT01206764: a trial of everolimis in patients with advanced renal cell carcinoma (EVERMORE). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
57. NCT01152801: safety of RAD001 in Chinese patients with metastatic renal cell cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
58. NCT00494091: study evaluating the safety, efficacy & pharmacokinetics of temsirolimus(CCI-779) in subjects with advanced renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
59. Armstrong AJ, George DJ, Halabi S (2010) Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 28(15s):abstr 4631
60. RA Figlin S Pd D McDermott JP Dutcher A Berkenblit A Thiele M Krygowski A Strahs J Feingold J Boni G Hudes 2009 Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha Cancer 115 16 3651 3660 19526589 10.1002/cncr.24438 1:CAS:528:DC%2BD1MXhtVOnurnJ
61. DJ Sargent BA Conley C Allegra L Collette 2005 Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 9 2020 2027 10.1200/jco.2005.01.112 15774793 10.1200/JCO.2005.01.112 (Pubitemid 46211382)
62. NCT00827359: biomarker trial of everolimus in patients with advanced renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
63. D Cejka C Kuntner M Preusser M Fritzer-Szekeres BJ Fueger S Strommer J Werzowa T Fuereder T Wanek M Zsebedics M Mueller O Langer V Wacheck 2009 FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo Br J Cancer 100 11 1739 1745 19436299 10.1038/sj.bjc.6605076 1:CAS:528:DC%2BD1MXmsVChtL4%3D
64. L Nogova R Boellaard C Kobe N Hoetjes T Zander SH Gross S Dimitrijevic T Pellas W Eschner K Schmidt C Bangard W Hayes RK Thomas M Dietlein G Giaccone OS Hoekstra AA Lammertsma J Wolf 2009 Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus J Nucl Med 50 11 1815 1819 19837761 10.2967/jnumed.109.065367
65. WW Ma H Jacene D Song F Vilardell WA Messersmith D Laheru R Wahl C Endres A Jimeno MG Pomper M Hidalgo 2009 [18F]Fluorodeoxyglucose positron emission tomography correlates with AKT pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy J Clin Oncol 27 16 2697 2704 19380450 10.1200/JCO.2008.18.8383 1:CAS:528:DC%2BD1MXnslWitLo%3D
66. NCT00529802: exploratory study evaluating fluorodeoxyglucose-position emission tomography as a predictive marker for therapy with RAD001 in metastatic renal cell cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
67. NCT01246817: temsirolimus-RCC-imaging. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
68. V Frings AJ de Langen EF Smit FH van Velden OS Hoekstra H van Tinteren R Boellaard 2010 Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer J Nucl Med 51 12 1870 1877 10.2967/jnumed.110.077255 21078791 10.2967/jnumed.110.077255
69. W Yang Y Zhang Z Fu J Yu X Sun D Mu A Han 2010 Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer Eur J Nucl Med Mol Imaging 37 7 1291 1299 10.1007/s00259-010-1412-6 20309686 10.1007/s00259-010-1412-6
70. Y Yamamoto Y Nishiyama N Kimura S Ishikawa M Okuda S Bandoh N Kanaji M Asakura M Ohkawa 2008 Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer Eur J Nucl Med Mol Imaging 35 2 236 245 10.1007/s00259-007-0613-0 17909790 10.1007/s00259-007-0613-0 1:CAS:528:DC%2BD1cXosVehtQ%3D%3D
71. T Saga H Kawashima N Araki JA Takahashi Y Nakashima T Higashi N Oya T Mukai M Hojo N Hashimoto T Manabe M Hiraoka K Togashi 2006 Evaluation of primary brain tumors with FLT-PET: usefulness and limitations Clin Nucl Med 31 12 774 780 10.1097/01.rlu.0000246820.14892.d2 17117071 10.1097/01.rlu.0000246820.14892. d2 (Pubitemid 44789556)
72. W Chen T Cloughesy N Kamdar N Satyamurthy M Bergsneider L Liau P Mischel J Czernin ME Phelps DH Silverman 2005 Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 46 6 945 952 15937304 1:CAS:528:DC%2BD28XitFSqtrw%3D (Pubitemid 43733508)
73. NCT01224288: Renal Cell Carcinoma (RCC) scramble. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
74. NCT01028638: VEGF imaging before and during everolimus treatment for renal cell carcinoma (Everolimage). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
75. NCT01037257: a safety study of LBH589 (Panobinostat) and RAD001 (Everolimus) to stabilize kidney cancer. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
76. NCT01198158: everolimus with or without bevacizumab in treating patients with advanced kidney cancer that progressed after first-line therapy. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
77. NCT01239342: MK2206 or everolimus in treating patients with refractory kidney cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
78. NCT01218555: study of everolimus (RAD001) in combination with lenalidomide in patients with advanced solid malignancies enriched for renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
79. NCT01115803: a study of LY2584702 with erlotinib or everolimus in patients with solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
80. NCT00303732: vatalanib and everolimus in treating patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
81. NCT00651482: treatment of refractory metastatic renal cell carcinoma with bevacizumab and RADOO1. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
82. NCT00422344: a study of RAD001 and sunitinib in metastatic renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
83. NCT01034631: BNC105P in combination with everolimus/following everolimus for progressive metastatic clear cell renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
84. NCT00384969: sorafenib and RAD001 renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
85. NCT00719264: safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab in adult patients with kidney cancer (L2201). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
86. NCT00331409: everolimus and imatinib mesylate in treating patients with metastatic or unresectable kidney cancer. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
87. NCT00655655: everolimus and vatalanib in treating patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
88. NCT00392821: dosing and effectiveness study of sorafenib and RAD001 in the treatment of patients with advanced kidney cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
89. NCT00323739: bevacizumab (Avastin) and RAD001(Everolimus) in the treatment of advanced clear cell renal carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
90. NCT00985374: a multiple ascending dose study of the mTOR inhibitor (RAD001) in combination with R1507 in patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
91. NCT01184326: pazopanib and everolimus in patients with advanced solid tumors and previously treated kidney cancer. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
92. NCT00788060: a phase Ib study of Rad001 and sutent to treat renal cell carcinoma (Rad/Sutent). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
93. NCT01136733: a study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior Vascular Endothelial Growth Factor (VEGF)-targeted treatment. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
94. NCT00448149: phase I/II trial of RAD001 plus nexavar in patients with kidney cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
95. NCT00903175: efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma. Available at: http://www.ClinicalTrials.gov ; last accessed June 23, 2009
96. NCT00831480: everolimus(RAD001) for advanced Renal Cell Carcinoma(RCC) before kidney removal. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
97. NCT01185366: everolimus versus sunitinib in non-clear cell renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
98. NCT00700258: registry for temsirolimus and sunitinib treated patients with Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
99. NCT00112840: CCI-779 and bevacizumab in treating patients with metastatic or unresectable kidney cancer. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
100. NCT00782275: avastin and temsirolimus following tyrosine kinase inhibitor failure in patients with advanced renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
101. NCT00563147: a phase 1b, open-label, dose-finding study to evaluate the safety of tivozanib (AV-951) in combination with temsirolimus in subjects with metastatic renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
102. NCT00417677: a study combining treatment with temsirolimus and sunitinib for subjects with advanced renal cell carcinoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
103. NCT00065468: study evaluating interferon and CCI-779 in Advanced Renal Cell Carcinoma (ARCC). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
104. NCT00378703: bevacizumab, sorafenib, and temsirolimus in treating patients with metastatic kidney cancer. Available at: http://www.clinicaltrials. gov ; last accessed December 4, 2010
105. NCT00619268: combination of temsirolimus and bevacizumab in patient with metastatic renal cell carcinoma (TORAVA). Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
106. NCT01079286: study of nelfinavir and temsirolimus in patients with advanced cancers (I-NET). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
107. NCT00112476: temsirolimus and bryostatin 1 in treating patients with unresectable or metastatic solid tumors. Available at: http://www. clinicaltrials.gov ; last accessed December 4, 2010
108. NCT00600496: a phase I, open-label, multi-center study to assess the safety, tolerability and pharmacokinetics of AZD6244 (ARRY-142886). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
109. NCT01198184: RO4929097 and temsirolimus in treating patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
110. NCT01122615: sunitinib plus temsirolimus in patients with Renal Cell Cancer (RCC). Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
111. NCT01155258: temsirolimus and vinorelbine ditartrate in treating patients with unresectable or metastatic solid tumors. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
112. NCT00659568: metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010
113. NCT00538772: an exploratory correlative study of biomarkers in patients with metastatic renal cell carcinoma who have progressed after sunitinib therapy. Available at: http://www.clinicaltrials.gov ; last accessed December 4, 2010